BioNTech 거래 BNTX

매도
 매수

BioNTech 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

최신 뉴스

Frances Wang 2025 Apr 07, 16:00

Stock Market Today: Dow, S&P 500 Drop, Nasdaq Rises in Volatile Session

Indices Stocks
Tommy Yap 2025 Apr 07, 16:00

Morning Note: Trade Fears Hit Nvidia, Deepen US-China Clash; UK Seeks US Deal

Morning Note USD China
Frances Wang 2025 Apr 06, 16:00

Monthly Economic Report: Insights into Growth and Trends

Fed
Tommy Yap 2025 Apr 06, 16:00

Morning Note: Markets Tumble on Tariffs, Bitcoin Below $80K & Yen Gains

Morning Note Cryptocurrencies Forex
Tommy Yap 2025 Apr 05, 16:00

Week Ahead: Will U.S. Inflation Data Surprise the Market?

Forex Indices
Tommy Yap 2025 Apr 03, 16:00

Morning Note: Oil Prices Slide, US NFP Preview, Canada Jobs Data

Morning Note Oil Forex Commodities
Frances Wang 2025 Apr 02, 16:00

USD/JPY Forecast: Analyzing Market Trends and Economic Indicators

Forex
Tommy Yap 2025 Apr 02, 16:00

Morning Note: U.S. Tariffs Shake Markets, Nikkei Sinks & Swiss Inflation Data Awaits

Morning Note USD

정보

스프레드

0.6284

스프레드(%)

0.7299 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 폐장

수요일

13:31 - 19:59

월요일

13:31-19:59

화요일

13:31-19:59

목요일

13:31-19:59

금요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

21129447424

발행 주식 수

239971008

수익 날짜 (다음)

0000-00-00

배당수익률

2022-06-17

배당락일

2022-06-02

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

-3.02

이 상품에 대해 자세히 알아보기

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments
Trustpilot